# US 2020/0390890 A1 · Antibacterial photodynamic therapy using copper-cysteamine nanoparticles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390890 A1
- Document ID: US20200390890A1
- Status: Published application
- Kind: A1
- Application number: 16/901,602
- Filed: 2020-06-15
- Published: 2020-12-17
- Earliest claimed: 2019-06-14
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, the University of Texas System
- Inventors: Wei Chen
- Web page: https://patentgrep.com/patent/US20200390890A1

## CPC

- A61K 41/0057: {Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}
- A01N 37/02: Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
- A01N 37/06: Unsaturated carboxylic acids or thio analogues thereof; Derivatives thereof
- A01N 55/02: containing metal atoms
- A01N 59/12: Iodine, e.g. iodophors; Compounds thereof
- A01N 59/20: Copper
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 31/30: Copper compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61N 5/0624: {for eliminating microbes, germs, bacteria on or in the body}
- A61P 31/04: Antibacterial agents
- C12Q 1/14: Streptococcus; Staphylococcus
- A61N 5/02: using microwaves
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61N 2005/0651: {Diodes}
- A61N 2005/0654: {Lamps}
- A61N 2005/0661: {ultraviolet}
- A61N 2005/1087: {Ions; Protons}
- A61N 2005/1089: {Electrons}
- A61N 2005/109: {Neutrons}
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The uses of the disclosed copper-cysteamine (Cu-Cy) complex for methods for treating Gram-positive and Gram-negative infections in subjects and for disinfecting a surface are disclosed. In addition, the disclosed Cy-Cy nanoparticles provide Fenton-like reactions in vivo, in vitro and ex vivo.

## Claims

### Claim 1

A method for treating a subject having a bacterial infection, comprising:
a) administering to a subject having a bacterial infection an effective amount of nanoparticles containing a compound having the formula:
Cu3Cl(SR)2
wherein R is —CH2CH2NH2 such that the bacteria are in contact with the compound; and
b) exposing the compound to a photo-activating amount of electromagnetic radiation at a wavelength that actives the compound.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the bacteria is a Gram-positive bacteria.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the bacteria is chosen from Streptococcus pyrogenes, Streptococcus agalactiae, Streptococcus faecalis, Streptococcus pneumoniae, Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus, and Enterococcus faecalis.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the source of radiation is chosen from ultra violet rays, microwave radiation, an X-ray source, a gamma-ray source, a beta-ray source, a source of proton emission, a source of electron emission, or a source of neutron emission.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the amount of compound administered is from about 1 μM to about 100 μM.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the compound is administered more than once.

### Claim 7

A method for treating an infected wound, comprising:
a) identifying the presence of bacteria in a wound;
b) contacting the wound with Copper-Cysteamine nanoparticles;
c) exposing the wound to a source of ultra violet light; and
d) culturing a sample taken from the wound to determine the presence of the bacteria.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the bacteria is a Gram-positive bacteria.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the bacteria is chosen from Streptococcus pyrogenes, Streptococcus agalactiae, Streptococcus faecalis, Streptococcus pneumoniae, Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus, and Enterococcus faecalis.

### Claim 10 (depends on 7)

The method according to claim 7, wherein the source of radiation is chosen from ultra violet rays, microwave radiation, an X-ray source, a gamma-ray source, a beta-ray source, a source of proton emission, a source of electron emission, or a source of neutron emission.

### Claim 11 (depends on 7)

The method according to claim 7, wherein the amount of compound administered is from about 1 μM to about 100 μM.

### Claim 12 (depends on 7)

The method according to claim 7, wherein radiation is applied to the wound until there are no bacteria present.

### Claim 13

A method for treating a bacterial infection in a subject, comprising contacting a subject having a bacterial infection with an effective amount of a composition comprising:
a) copper-cysteamine having the formula:
Cu3Cl(SR)2
wherein R is —CH2CH2NH2; and
b) an organic acid;
wherein the pH of the composition is from about 3.0 to about 7.0.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the composition undergoes Fenton-like reactions against the bacteria.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the bacteria is a Gram-positive bacteria.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the bacteria is chosen from Streptococcus pyrogenes, Streptococcus agalactiae, Streptococcus faecalis, Streptococcus pneumoniae, Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus, and Enterococcus faecalis.

### Claim 17 (depends on 13)

The method according to claim 13, wherein the bacteria is a Gram-negative bacteria

### Claim 18 (depends on 17)

The method according to claim 17, wherein the bacteria is Escherichia coli.

### Claim 19

A composition comprising:
a) copper-cysteamine having the formula:
Cu3Cl(SR)2
wherein R is —CH2CH2NH2;
b) an organic acid; and
c) a carrier;
wherein the pH of the composition is from about 3 to about 7.

### Claim 20 (depends on 19)

The composition according to claim 19, wherein the organic acid is chosen from acetic acid, lactic acid, citric acid, oxalic acid, malic acid, maleic acid, tartaric acid, glycolic acid, propionic acid, malonic, or fumaric acid.
